Liposomal irinotecan, chemotherapy, and bevacizumab for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with colon or rectal cancer that has spread to other parts of the body and cannot be surgically removed.
- Your first treatment for advanced disease included a drug called oxaliplatin.
- You have at least one tumor that can be measured on scans.
- Your overall health status allows you to be up and about (ECOG score 0-2).
- You have adequate organ function (liver, kidneys, blood counts) based on standard lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This study tests a new form of the chemotherapy drug irinotecan (liposomal irinotecan) for people with metastatic colorectal cancer whose first treatment with oxaliplatin-based therapy has stopped working. The goal is to see if this drug can help shrink or control the cancer.
This trial tests a new form of the chemotherapy drug irinotecan (called irinotecan liposome) combined with two other chemo drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has already been treated with oxaliplatin. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.